Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies reports developments tied to its role as a supplier of ion implantation systems and process applications for semiconductor manufacturing. Company updates commonly cover quarterly results, demand trends across memory, power, compound semiconductor and mature-node markets, and the performance of its customer support and installed-base services business.
News also includes technical participation at semiconductor industry conferences, lifecycle support for Purion-based implant platforms, sustainability targets for greenhouse gas emissions, investor-conference activity and governance changes such as finance leadership transitions. The recurring business context centers on equipment used in integrated-circuit fabrication and aftermarket services including spare parts, upgrades, maintenance and training.
Axcelis Technologies (Nasdaq: ACLS) will exhibit at SEMICON Korea 2026 in Seoul, Feb 11–13, at COEX Center, Booth #D522. The company will showcase the Purion platform and introduce the next‑generation Purion H6 high current implanter.
Axcelis' presentation on ion implantation applications will be delivered by Dr. KyungWon Lee on Feb 11 at 3:15pm in Conference Room #308.
Axcelis (NASDAQ: ACLS) on Feb. 4, 2026 unveiled the Purion H6, a next‑generation high current ion implanter built for advanced semiconductor manufacturing. The system emphasizes dose control, enhanced particle control, Eterna ELS7 source technology, higher beam currents and improved throughput, reliability and lower cost of ownership.
The Purion H6 targets logic, advanced memory, image sensor and mature technology segments and will be exhibited at SEMICON Korea, Feb. 11–13, booth #D522.
Axcelis (Nasdaq: ACLS) will release fourth quarter and full year 2025 financial results after market close on Tuesday, February 17, 2026. The company will host a conference call the same day at 5:00 p.m. ET to discuss results. The call is available via webcast on Axcelis' Investors page or by registering at the provided registration link. Webcast replays will be available for 30 days after the call.
Whirlpool (NYSE: WHR) received public praise from the mayors of Clyde and Marion, Ohio for its sustained U.S. manufacturing commitment on Jan 15, 2026. The company employs about 4,500 workers across the two Ohio sites; the Clyde plant (in operation since 1952) is described as the largest washing machine plant in the world and Marion recently marked its 70th anniversary. On Oct 15, 2025, Whirlpool announced a $300 million investment in these factories, expected to create up to 600 new jobs, reinforcing local economic impact and long-term manufacturing presence in Ohio.
Axcelis (NASDAQ: ACLS) announced that management will participate in the 28th Annual Needham Growth Conference on January 13, 2026 at The Lotte NY Palace Hotel in New York, NY.
Management is available for one-on-one and group meetings with investors during the conference, offering opportunities to discuss strategy and outlook with company executives.
Axcelis (Nasdaq: ACLS) will exhibit at SEMICON Japan 2025, December 17–19 at Tokyo Big Sight, in Hall 2, Booth #2655. The company will showcase next‑generation ion implant systems aimed at improving device performance, productivity, and cost of ownership for power, image sensor, memory, and advanced logic markets.
Featured systems include Purion Power Series+ (new SiC extensions), Purion H Series, Purion XE Series (up to 15 MeV) and GSD Ovation ES. On Dec 18 Axcelis will present a TechSPOT talk at 15:30 and host a company happy hour at 16:00 in Booth #2655.
Axcelis (NASDAQ: ACLS) will participate in two investor conferences this fall and winter 2025: the Wells Fargo 9th Annual TMT Summit on November 18, 2025 at Terranea Resort in Rancho Palos Verdes, CA, and the 14th Annual NYC Summit on December 16, 2025 at Mastro's Steakhouse in New York, NY.
The appearances present opportunities for investor updates and meetings with company management during the specified dates and venues.
Axcelis (Nasdaq: ACLS) reported third-quarter 2025 results with revenue of $213.6 million, GAAP gross margin of 41.6% and GAAP diluted EPS of $0.83. Non-GAAP diluted EPS was $1.21 and Adjusted EBITDA was $43.2 million. Management highlighted record CS&I revenue, strong operating leverage, and over $590 million in cash and investments on the balance sheet.
The company provided fourth-quarter 2025 guidance of approximately $215 million revenue, GAAP EPS of about $0.76, and non-GAAP EPS of about $1.12. Management reiterated the proposed merger with Veeco Instruments as a strategic milestone intended to create a larger semiconductor equipment company.
Axcelis (Nasdaq: ACLS) will release third quarter 2025 financial results before market open on Tuesday, November 4, 2025. The company will host a conference call the same day at 8:30 a.m. ET to discuss the results.
The call will be available via webcast on the Investors page at www.axcelis.com or by registering at the provided registration link. Webcast replays will be available for 30 days after the call.
Axcelis Technologies (NASDAQ:ACLS) and Veeco Instruments have announced a transformative all-stock merger creating a semiconductor equipment company with an estimated $4.4 billion enterprise value. Under the agreement, Veeco shareholders will receive 0.3575 Axcelis shares for each Veeco share, resulting in Axcelis shareholders owning 58% and Veeco shareholders 42% of the combined entity.
The merged company will be headquartered in Beverly, Massachusetts, with Dr. Russell Low as CEO. On a pro-forma basis for FY2024, the combined company generated $1.7 billion in revenue, 44% non-GAAP gross margin, and $387 million in adjusted EBITDA. The merger is expected to achieve $35 million in annual cost synergies within 24 months and be accretive to non-GAAP earnings per share within the first year post-closing.
The transaction is anticipated to close in second half of 2026, subject to shareholder and regulatory approvals.